New Study: Ketamine Relieves Treatment-Resistant Depression

Ketamine Study Highlights Relief for Treatment-Resistant Depression

A new study highlighted by The Jerusalem Post on June 28, 2026, adds to the growing body of evidence supporting ketamine as a treatment for resistant depression and suicidal ideation — two of the most difficult presentations in mental health care.

The article's reference to ketamine as "the party drug" reflects how the substance is often framed in mainstream media — a shorthand that captures its recreational history but can obscure its clinical significance. For the millions of people who have not responded to standard antidepressants, ketamine represents something quite different: a rapid-acting treatment with a pharmacological profile unlike anything else in psychiatry's toolkit.

Why Ketamine Works Differently Than Conventional Antidepressants

Most conventional antidepressants — SSRIs, SNRIs, and tricyclics — work primarily through the serotonin system and require four to six weeks of consistent use before patients notice meaningful improvement. Ketamine operates through a different pathway: it primarily blocks NMDA (N-methyl-D-aspartate) receptors in the brain, a key component of glutamate signaling. This distinction is clinically important because it allows ketamine to produce antidepressant effects within hours to days rather than weeks.

For people experiencing acute suicidal ideation, that speed matters enormously. Traditional antidepressants require sustained use before any protective effect builds — a gap that leaves the most vulnerable patients at continued risk. Ketamine's rapid onset has made it an area of intense research interest specifically because it can address acute suicidal crises in ways that slower-acting medications cannot.

The U.S. Food and Drug Administration took formal note of this potential in 2019, approving esketamine (brand name Spravato) — a nasal spray form of ketamine's S-enantiomer — for treatment-resistant depression, and later for major depressive disorder with active suicidal ideation or behavior. That approval separated ketamine's clinical identity from its recreational reputation and positioned it within mainstream psychiatry, though IV ketamine infusions, widely used off-label by specialized clinics, remain outside the direct scope of that approval.

The 'Party Drug' Label: Useful Shorthand or Misleading Framing?

Media coverage of ketamine frequently relies on its nightclub associations to generate attention — and the juxtaposition of a club drug and severe depression is genuinely surprising to general audiences. But this framing carries real costs for patients navigating treatment decisions.

When someone is struggling with depression that has not responded to two or more antidepressant trials — the standard clinical definition of treatment-resistant depression — the "party drug" label can make it harder to take ketamine seriously as a medical option or to raise it with a physician or psychiatrist. It also conflates the carefully dosed, monitored clinical setting with uncontrolled recreational use, which are not remotely comparable in terms of safety oversight, dosing precision, or context.

Treatment-resistant depression affects an estimated 30% of people with major depressive disorder — a substantial population that has exhausted first- and second-line options and often carries a significant burden of suffering alongside elevated suicide risk. For this group, evidence-backed options deserve clear, accurate framing rather than reflexive sensationalism.

What Patients Should Know Before Pursuing Ketamine Treatment

Coverage of new ketamine studies can generate enthusiasm that outpaces the practical questions patients need to answer before moving forward. Here is what current evidence and clinical practice suggest:

• Two main pathways exist. FDA-approved esketamine nasal spray (Spravato) is administered in a certified healthcare setting and covered by some insurance plans, particularly for treatment-resistant depression. IV ketamine infusions are offered off-label by ketamine clinics and psychiatry practices; costs vary widely and insurance coverage is less consistent.
• Not everyone qualifies. People with active or recent psychosis, certain cardiovascular conditions, or specific substance use histories may not be appropriate candidates. A thorough psychiatric and medical evaluation is standard before treatment begins.
• Effects are not always permanent. Many patients experience meaningful relief following a series of infusions or esketamine sessions, but depression can return over time. Maintenance dosing and integration with ongoing psychiatric care are standard elements of long-term treatment planning.
• Monitoring is built into clinical protocols. Ketamine can produce dissociative effects during administration. Clinical protocols include vital sign monitoring and post-dosing supervision — typically at least two hours for esketamine — and comparable precautions apply in IV ketamine settings.

The accumulation of research flagged in studies like the one covered by The Jerusalem Post reinforces what clinicians working in this area have been observing in practice: ketamine is a meaningful tool for a population that has traditionally had very limited options. The ongoing challenge is ensuring that public understanding keeps pace with the science — and that patients who could benefit have access to accurate information and qualified providers rather than a framing built around the drug's most sensational history.